The Alzheimer Society Research Portal connects researchers with Canadians looking to participate in research studies. On this website, find active studies that you can participate in to help advance research on dementia.
This study is looking for caregivers to take part in a six-week creative movement group program, which aims to improve mental well-being and resilience.
You are eligible to participate if you: identify as a primary caregiver for a family member (e.g., parent) or partner/spouse living with dementia.
The study is entitled, “CIRCA-SK: Promoting social connection between people with dementia and caregivers,” and involves using a computer-based reminiscence tool to promote conversation between people living with dementia and their caregivers. The tool has been adapted to include content – photos, videos, and audio clips – that reflects life in Saskatchewan between the 1940s and 1980s. The content is generic, and sorted into categories, such as, “School Days,” “Working Life,” and “Entertainment.” The tool has been used successfully in the UK, and is now being adapted for audiences in Canada.
-are a care partner to someone with dementia
-are a person living with dementia (which will be determined by a telephone assessment)
-are the facilitator of a group of people living with dementia (i.e., a conversation circle or day program)
-ability to speak English
Caregivers of people living with dementia experience significant stress which can negatively affect their mental health. The overall aim of the current study is to evaluate a newly developed app that focuses on providing stress-management strategies for family caregivers of people living with dementia. Findings from the study of an app that aims to address the stressors associated with caregiving has the potential to improve the quality of life of caregivers of people living with dementia.
- Providing informal and unpaid care (e.g., spouses, children) for people living with dementia
- Providing primary care (i.e., most of the care or equally shares the care with another individual such as a mother or sibling) for the person living with dementia
- Own a smartphone (e.g., iPhone, Android)
- Not currently using a mobile app created for caregivers
- Ability to speak English
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Age 50 - 85
Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease
Must have a study partner
The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.
60+
Diagnosis of Alzheimer's disease
Must have a study partner
The goal of the proposed SYNERGIC-2 TRIAL (SYNchronizing Exercises, and Remedies to GaIn Cognition@home) is to evaluate cognitive improvements from personalized multidomain interventions that target multiple dementia risk factors delivered at home to older adults with Mild Cognitive Impairment (MCI).
- Aged 60-85 years.
- Concerned about memory or thinking problems.
- Have access to internet at home.
- Ability to speak English.
It is expected that the information collected during this study will be used in analyses and will be published/presented to the scientific community at meetings and in journals. This information may also be used as part of a submission to regulatory authorities around the world to support the approval of the study intervention for agitation in AD.
You are eligible to participate if you meet the following criteria:
• Age ≥ 55; females must be post-menopausal
• DSM-5 criteria for Major Neurocognitive Disorder due to AD; multiple etiologies (AD and vascular)
• sMMSE ≤ 24
• Clinically significant agitation based on IPA definition
• Stable cognition-enhancing medication for at least 3 months prior to study enrolment
• Availability of a caregiver to accompany participant to study visits and to participate in the study
• Ability to speak English
To examine the effects of a stress management program on well-being, stress, and cognition in family caregivers of someone with dementia or a related neurodegenerative disorder. We will be recruiting participants from 2023 - 2027.
- are a primary family caregiver of a person with dementia or a related neurodegenerative disorder.
- have access to a computer with high-speed internet; and feel comfortable using email and Zoom (a secure online meeting platform).
- have a video camera on your device. To ensure safety of participants during the program sessions, it is important that participants turn on their video camera. Keeping the video camera on is also important to build trust within the group sessions and when interacting with the researchers.
- are willing to be randomised to one of 3 groups, even if it is not your preferred group.
- are able to commit to a synchronous 8-week online group-based program (described below) and complete daily prescribed daily home practices.
- are able to commit to three assessment sessions: one baseline assessment, one post-program assessment, one 12-month follow-up assessment.
- agree to audio recording of interview sessions and portions of the assessment that require accurate verbal data collection.
- are able to provide blood samples, potentially after a 12-hour fast.
- are able to travel to a LifeLabs clinic for biomarker collection.
- agree to refrain from participating in new studies or programs during the 8-week study session.
- meet the screening criteria during the pre-screening interview.
- ability to speak English.
This Phase 2 study aims to study to evaluate the efficacy and safety of study treatment in paticipants with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia
Age 50 - 80
Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease
Follow us: